Editas Medicine
EDIT
225 hedge funds and large institutions have $504M invested in Editas Medicine in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 63 reducing their positions, and 35 closing their positions.
106% more call options, than puts
Call options by funds: $5.57M | Put options by funds: $2.71M
14% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 63
9.48% more ownership
Funds ownership: 73.56% → 83.04% (+9.5%)
9% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 35
0% more funds holding
Funds holding: 225 → 225 (0)
17% less capital invested
Capital invested by funds: $609M → $504M (-$105M)
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$30.7M |
| 2 |
Goldman Sachs
New York
|
+$7.04M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$5.5M |
| 4 |
Millennium Management
New York
|
+$5.37M |
| 5 |
Citigroup
New York
|
+$4.5M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$6.19M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.88M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$4.27M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$2.66M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.15M |
EDIT Hedge Fund Activity: Q1 2024 in Review
225 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2024, worth a combined $504M — down 17% from $609M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new EDIT positions and 35 closed out — a net gain of 3 holders — while 72 added to existing stakes and 63 trimmed.
The largest buyer was State Street, adding an estimated $30.7M. The largest seller was Morgan Stanley, cutting an estimated $6.19M.
- 225 institutional investors held Editas Medicine (EDIT) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $504M of Editas Medicine stock for Q1 2024, down 17% quarter-over-quarter.
- 38 funds opened new Editas Medicine positions in Q1 2024 and 35 closed out, a net change of +3 holders.
- The largest Editas Medicine buyer in Q1 2024 was State Street, an estimated $30.7M added.
- The largest Editas Medicine seller in Q1 2024 was Morgan Stanley, an estimated $6.19M sold.
Based on aggregated 13F filings for Q1 2024.